Why the world shouldn’t dismiss North Korea’s COVID-19 vaccine trials
North Korea's increased investment and emphasis on research means COVID-19 clinical trials might actually be underway
On July 18, North Korea announced that a domestically produced COVID-19 vaccine entered clinical trials, joining the global race to develop a cure for a virus that has already killed at least 650,000 people worldwide.
An otherwise quiet North Korean state website, Mirae, first published the report, which was then quickly picked up by South Korean media and even CNN. The New York Times went so far as to add the North Korean clinical trial to its vaccine tracker.
Nevertheless, news media was quick to stress doubt that the DPRK had the funds or expertise to develop
- 01Rail trade with North Korea threatened as COVID surges in Chinese border city
- 02Prominent promotions: North Korea’s new generals and ‘hero’ missile transporter
- 03FULL TEXT: North Korea’s death penalty decree for spreading COVID ‘rumors’
- 04North Korean insurance companies increase profits despite pandemic and lockdown
- 05State media review: North Korea rewards greenhouse workers with new homes
- 06What metadata reveals about North Korea’s latest long-range missile test
- 07How non-defecting border crossers can bring change to North Korea
- 08Scorched Earth: How climate change could send North Korea up in flames